...
首页> 外文期刊>Allergy >Decline of Ves v 5-specific blocking capacity in wasp venom-allergic patients after stopping allergen immunotherapy
【24h】

Decline of Ves v 5-specific blocking capacity in wasp venom-allergic patients after stopping allergen immunotherapy

机译:停止过敏原免疫治疗的黄蜂毒过敏患者中Ves v 5特异性阻断能力的下降

获取原文
获取原文并翻译 | 示例
           

摘要

While allergen-specific immunotherapy (AIT) is very efficient in hymenoptera venom (HV)-allergic patients, long-term outcome after finishing AIT is not well investigated, especially regarding mechanisms that are suggested to contribute to allergen-specific tolerance. Here, we analyse the Ves v 5-inhibitory activity of sera from wasp venom-allergic patients using the novel cell-free enzyme-linked immunosorbent facilitated antigen binding (ELIFAB) assay. Compared to pre-AIT, sera from patients undergoing AIT displayed an increased ability to inhibit Ves v 5 binding by IgE antibodies. In contrast, this inhibitory activity was reduced in patients having finished AIT 5-12years ago. Allergen-blocking capacity correlated with serum concentrations of Ves v 5-specific IgG4 which rose during AIT but almost reached pretreatment levels in patients who had stopped AIT more than 5years ago. These data raise questions about how long allergen tolerance is maintained in AIT-treated HV-allergic patients and suggest that the ELIFAB assay might be an easy-to-use tool assessing long-term tolerance in patients treated with HV-AIT.
机译:虽然过敏原特异性免疫疗法(AIT)在膜翅目毒液(HV)过敏性患者中非常有效,但对AIT结束后的长期结局还没有很好的研究,特别是关于提示有助于过敏原特异性耐受的机制。在这里,我们使用新型的无细胞酶联免疫吸附促进抗原结合(ELIFAB)分析方法分析了黄蜂毒液过敏患者血清的Ves v 5抑制活性。与AIT前相比,来自AIT患者的血清显示出更高的抑制IgE抗体结合Ves v 5的能力。相反,在5至12年之前完成AIT的患者中,这种抑制活性降低了。阻断变应原的能力与Ves v 5特异性IgG4的血清浓度相关,后者在AIT期间升高,但在5年前停止AIT的患者中几乎达到了治疗前的水平。这些数据引发了有关在AIT治疗的HV过敏患者中维持多长时间的过敏原耐受性的疑问,并表明ELIFAB分析可能是评估HV-AIT治疗的患者长期耐受性的易于使用的工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号